208 related articles for article (PubMed ID: 32772418)
21. Improved engraftment of human peripheral blood mononuclear cells in NOG MHC double knockout mice generated using CRISPR/Cas9.
Ka Y; Katano I; Nishinaka E; Welcker J; Mochizuki M; Kawai K; Goto M; Tomiyama K; Ogura T; Yamamoto T; Ito M; Ito R; Takahashi R
Immunol Lett; 2021 Jan; 229():55-61. PubMed ID: 33253759
[TBL] [Abstract][Full Text] [Related]
22. HIV Replication and Latency in a Humanized NSG Mouse Model during Suppressive Oral Combinational Antiretroviral Therapy.
Satheesan S; Li H; Burnett JC; Takahashi M; Li S; Wu SX; Synold TW; Rossi JJ; Zhou J
J Virol; 2018 Apr; 92(7):. PubMed ID: 29343582
[TBL] [Abstract][Full Text] [Related]
23. Evaluating Human Immune Responses for Vaccine Development in a Novel Human Spleen Cell-Engrafted NOD-SCID-IL2rγNull Mouse Model.
Ghosn S; Chamat S; Prieur E; Stephan A; Druilhe P; Bouharoun-Tayoun H
Front Immunol; 2018; 9():601. PubMed ID: 29628927
[TBL] [Abstract][Full Text] [Related]
24. NOD/scid IL-2Rg(null) mice: a preclinical model system to evaluate human dendritic cell-based vaccine strategies in vivo.
Spranger S; Frankenberger B; Schendel DJ
J Transl Med; 2012 Feb; 10():30. PubMed ID: 22364226
[TBL] [Abstract][Full Text] [Related]
25. Next-generation humanized NSG-SGM3 mice are highly susceptible to
Hung S; Kasperkowitz A; Kurz F; Dreher L; Diessner J; Ibrahim ES; Schwarz S; Ohlsen K; Hertlein T
Front Immunol; 2023; 14():1127709. PubMed ID: 36969151
[TBL] [Abstract][Full Text] [Related]
26. Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm.
Panoskaltsis N; McCarthy NE; Stagg AJ; Mummery CJ; Husni M; Arebi N; Greenstein D; Price CL; Al-Hassi HO; Koutinas M; Mantalaris A; Knight SC
Cancer Immunol Immunother; 2021 Apr; 70(4):1127-1142. PubMed ID: 33033851
[TBL] [Abstract][Full Text] [Related]
27. Different players generate positive responses in two in vitro cytokine assay formats with aqueous and immobilized TGN1412 analog.
Iwata Y; Harada A; Kubo C; Inoue T; Tabo M; Mishima M
Biochem Biophys Res Commun; 2018 Jul; 502(1):91-97. PubMed ID: 29787754
[TBL] [Abstract][Full Text] [Related]
28. Improved B cell development in humanized NOD
Jangalwe S; Shultz LD; Mathew A; Brehm MA
Immun Inflamm Dis; 2016 Dec; 4(4):427-440. PubMed ID: 27980777
[TBL] [Abstract][Full Text] [Related]
29. Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08.
Tabares P; Berr S; Römer PS; Chuvpilo S; Matskevich AA; Tyrsin D; Fedotov Y; Einsele H; Tony HP; Hünig T
Eur J Immunol; 2014 Apr; 44(4):1225-36. PubMed ID: 24374661
[TBL] [Abstract][Full Text] [Related]
30. Human immune system development and survival of non-obese diabetic (NOD)-scid IL2rγ(null) (NSG) mice engrafted with human thymus and autologous haematopoietic stem cells.
Covassin L; Jangalwe S; Jouvet N; Laning J; Burzenski L; Shultz LD; Brehm MA
Clin Exp Immunol; 2013 Dec; 174(3):372-88. PubMed ID: 23869841
[TBL] [Abstract][Full Text] [Related]
31. Human mesenchymal stem cells suppress donor CD4(+) T cell proliferation and reduce pathology in a humanized mouse model of acute graft-versus-host disease.
Tobin LM; Healy ME; English K; Mahon BP
Clin Exp Immunol; 2013 May; 172(2):333-48. PubMed ID: 23574329
[TBL] [Abstract][Full Text] [Related]
32. A novel hemolytic complement-sufficient NSG mouse model supports studies of complement-mediated antitumor activity in vivo.
Verma MK; Clemens J; Burzenski L; Sampson SB; Brehm MA; Greiner DL; Shultz LD
J Immunol Methods; 2017 Jul; 446():47-53. PubMed ID: 28390927
[TBL] [Abstract][Full Text] [Related]
33. Development of the first reference antibody panel for qualification and validation of cytokine release assay platforms - Report of an international collaborative study.
Vessillier S; Fort M; O'Donnell L; Hinton H; Nadwodny K; Piccotti J; Rigsby P; Staflin K; Stebbings R; Mekala D; Willingham A; Wolf B;
Cytokine X; 2020 Dec; 2(4):100042. PubMed ID: 33458650
[TBL] [Abstract][Full Text] [Related]
34. A simple whole blood bioassay detects cytokine responses to anti-CD28SA and anti-CD52 antibodies.
Bailey L; Moreno L; Manigold T; Krasniqi S; Kropshofer H; Hinton H; Singer T; Suter L; Hansel TT; Mitchell JA
J Pharmacol Toxicol Methods; 2013; 68(2):231-239. PubMed ID: 23280407
[TBL] [Abstract][Full Text] [Related]
35. Humanized mouse model of mast cell-mediated passive cutaneous anaphylaxis and passive systemic anaphylaxis.
Bryce PJ; Falahati R; Kenney LL; Leung J; Bebbington C; Tomasevic N; Krier RA; Hsu CL; Shultz LD; Greiner DL; Brehm MA
J Allergy Clin Immunol; 2016 Sep; 138(3):769-779. PubMed ID: 27139822
[TBL] [Abstract][Full Text] [Related]
36. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
Ito A; Ishida T; Utsunomiya A; Sato F; Mori F; Yano H; Inagaki A; Suzuki S; Takino H; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
J Immunol; 2009 Oct; 183(7):4782-91. PubMed ID: 19748990
[TBL] [Abstract][Full Text] [Related]
37. Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release.
Eastwood D; Bird C; Dilger P; Hockley J; Findlay L; Poole S; Thorpe SJ; Wadhwa M; Thorpe R; Stebbings R
Br J Clin Pharmacol; 2013 Aug; 76(2):299-315. PubMed ID: 23701319
[TBL] [Abstract][Full Text] [Related]
38. The Combination of Patient Profiling and Preclinical Studies in a Mouse Model Based on NOD/Scid IL2Rγ null Mice Reconstituted With Peripheral Blood Mononuclear Cells From Patients With Ulcerative Colitis May Lead to Stratification of Patients for Treatment With Adalimumab.
Jodeleit H; Caesar J; Villarroel Aguilera C; Sterz S; Holdt L; Beigel F; Stallhofer J; Breiteneicher S; Bartnik E; Siebeck M; Gropp R
Inflamm Bowel Dis; 2020 Mar; 26(4):557-569. PubMed ID: 31782956
[TBL] [Abstract][Full Text] [Related]
39. Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse.
Ashizawa T; Iizuka A; Nonomura C; Kondou R; Maeda C; Miyata H; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Katano I; Ito M; Akiyama Y
Clin Cancer Res; 2017 Jan; 23(1):149-158. PubMed ID: 27458246
[TBL] [Abstract][Full Text] [Related]
40. "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics.
Stebbings R; Findlay L; Edwards C; Eastwood D; Bird C; North D; Mistry Y; Dilger P; Liefooghe E; Cludts I; Fox B; Tarrant G; Robinson J; Meager T; Dolman C; Thorpe SJ; Bristow A; Wadhwa M; Thorpe R; Poole S
J Immunol; 2007 Sep; 179(5):3325-31. PubMed ID: 17709549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
